Cargando…

Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology

Molecular testing of thyroid fine‐needle aspiration specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. A recent prospective, double‐blinded, multicenter study repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikiforov, Yuri E., Baloch, Zubair W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519348/
https://www.ncbi.nlm.nih.gov/pubmed/30811896
http://dx.doi.org/10.1002/cncy.22112
_version_ 1783418624650772480
author Nikiforov, Yuri E.
Baloch, Zubair W.
author_facet Nikiforov, Yuri E.
Baloch, Zubair W.
author_sort Nikiforov, Yuri E.
collection PubMed
description Molecular testing of thyroid fine‐needle aspiration specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. A recent prospective, double‐blinded, multicenter study reported the results of the clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate fine‐needle aspiration cytology.
format Online
Article
Text
id pubmed-6519348
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65193482019-05-23 Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology Nikiforov, Yuri E. Baloch, Zubair W. Cancer Cytopathol Commentaries Molecular testing of thyroid fine‐needle aspiration specimens has been developed with the primary goals of resolving the uncertainty of indeterminate cytology and avoiding the diagnostic surgeries generally recommended for these patients. A recent prospective, double‐blinded, multicenter study reported the results of the clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate fine‐needle aspiration cytology. John Wiley and Sons Inc. 2019-02-27 2019-04 /pmc/articles/PMC6519348/ /pubmed/30811896 http://dx.doi.org/10.1002/cncy.22112 Text en © 2019 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Commentaries
Nikiforov, Yuri E.
Baloch, Zubair W.
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
title Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
title_full Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
title_fullStr Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
title_full_unstemmed Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
title_short Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology
title_sort clinical validation of the thyroseq v3 genomic classifier in thyroid nodules with indeterminate fna cytology
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519348/
https://www.ncbi.nlm.nih.gov/pubmed/30811896
http://dx.doi.org/10.1002/cncy.22112
work_keys_str_mv AT nikiforovyurie clinicalvalidationofthethyroseqv3genomicclassifierinthyroidnoduleswithindeterminatefnacytology
AT balochzubairw clinicalvalidationofthethyroseqv3genomicclassifierinthyroidnoduleswithindeterminatefnacytology